LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 430

Search options

  1. Article ; Online: Burden of hepatitis B and C in Europe calls for political impetus to accelerate elimination efforts.

    Pawlotsky, Jean-Michel

    The Lancet. Public health

    2023  Volume 8, Issue 9, Page(s) e666–e667

    MeSH term(s) Humans ; Hepatitis B/epidemiology ; Hepatitis B/prevention & control ; Europe/epidemiology
    Language English
    Publishing date 2023-08-26
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2468-2667
    ISSN (online) 2468-2667
    DOI 10.1016/S2468-2667(23)00179-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: New hepatitis B drug development disillusions: time to reset?

    Pawlotsky, Jean-Michel

    The lancet. Gastroenterology & hepatology

    2022  Volume 8, Issue 2, Page(s) 192–197

    Abstract: After more than 5 years of intense preclinical and clinical research, the development of new hepatitis B virus (HBV) drugs appears to be stalling. The main reasons for this are the major limitations of the developmental path, including the use of ... ...

    Abstract After more than 5 years of intense preclinical and clinical research, the development of new hepatitis B virus (HBV) drugs appears to be stalling. The main reasons for this are the major limitations of the developmental path, including the use of inappropriate endpoints for clinical development, the standards for efficacy and approval being too strict (functional cure after short finite treatment duration), expecting compounds to do what they cannot do because of their known targets and mechanisms of action, and hoping that one size will fit all, despite the fact that HBV infection is heterogeneous. A functional HBV cure cannot be easily attained with only a few weeks or months of treatment with the classes of compounds that are currently in development. Therefore, researchers, drug developers, and regulators need to establish a new consensus about endpoints that are both clinically relevant and achievable, and redefine the objectives, timelines, and pathways of new HBV drug development.
    MeSH term(s) Humans ; Hepatitis B, Chronic/drug therapy ; Antiviral Agents/therapeutic use ; Hepatitis B/drug therapy ; Hepatitis B virus ; Hepatitis B Surface Antigens
    Chemical Substances Antiviral Agents ; Hepatitis B Surface Antigens
    Language English
    Publishing date 2022-11-04
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2468-1253
    ISSN (online) 2468-1253
    DOI 10.1016/S2468-1253(22)00341-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus.

    Pawlotsky, Jean-Michel

    Journal of hepatology

    2020  Volume 73, Issue 4, Page(s) 752–754

    MeSH term(s) Antiviral Agents/therapeutic use ; Genotype ; Hepacivirus/genetics ; Hepatitis C/drug therapy ; Hepatitis C, Chronic/drug therapy ; Humans
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2020-07-27
    Publishing country Netherlands
    Document type Editorial ; Comment
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2020.06.029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2027: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: COVID-19 and the liver-related deaths to come.

    Pawlotsky, Jean-Michel

    Nature reviews. Gastroenterology & hepatology

    2020  Volume 17, Issue 9, Page(s) 523–525

    MeSH term(s) Betacoronavirus ; COVID-19 ; Cause of Death/trends ; Coronavirus Infections/complications ; Coronavirus Infections/epidemiology ; Global Health ; Humans ; Liver Diseases/etiology ; Liver Diseases/mortality ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; Survival Rate/trends
    Keywords covid19
    Language English
    Publishing date 2020-07-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2493722-8
    ISSN 1759-5053 ; 1759-5045
    ISSN (online) 1759-5053
    ISSN 1759-5045
    DOI 10.1038/s41575-020-0328-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6020: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 97: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Interferon-Free Hepatitis C Virus Therapy.

    Pawlotsky, Jean-Michel

    Cold Spring Harbor perspectives in medicine

    2020  Volume 10, Issue 11

    Abstract: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with ∼71 million chronically infected individuals worldwide. Treatment of patients with HCV-related liver disease has advanced considerably thanks to the development of new ... ...

    Abstract Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with ∼71 million chronically infected individuals worldwide. Treatment of patients with HCV-related liver disease has advanced considerably thanks to the development of new direct-acting antiviral drugs that are now administered as highly potent, safe, and well-tolerated combinations with a high barrier to resistance. International organizations, such as the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases jointly with the Infectious Diseases Society of America, or the World Health Organization have published detailed treatment guidelines. With these therapies becoming more and more widely available, elimination of hepatitis C as a public health threat by 2030 can now be envisaged in several countries. In other regions, better screening, diagnosis, and linkage to care will be necessary to achieve this ambitious goal.
    MeSH term(s) Antiviral Agents/therapeutic use ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Humans ; Interferons/therapeutic use ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/etiology ; Practice Guidelines as Topic ; Ribavirin/therapeutic use ; Sustained Virologic Response
    Chemical Substances Antiviral Agents ; Ribavirin (49717AWG6K) ; Interferons (9008-11-1)
    Language English
    Publishing date 2020-11-02
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2157-1422
    ISSN (online) 2157-1422
    DOI 10.1101/cshperspect.a036855
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir.

    Pawlotsky, Jean-Michel

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 71, Issue 16, Page(s) 2191–2194

    Abstract: December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called coronavirus disease 2019 (COVID-19), caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2). No therapeutic option is ...

    Abstract December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called coronavirus disease 2019 (COVID-19), caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2). No therapeutic option is available to treat this infection that has already killed > 310 000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the life cycle of many coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at risk of severe forms of SARS-CoV-2 infection.
    MeSH term(s) Animals ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/epidemiology ; Clinical Trials as Topic ; Cyclophilins/antagonists & inhibitors ; Cyclosporine/therapeutic use ; Disease Models, Animal ; Humans ; Mice ; Rats ; SARS-CoV-2/drug effects
    Chemical Substances Antiviral Agents ; Cyclosporine (83HN0GTJ6D) ; Cyclophilins (EC 5.2.1.-) ; alisporivir (VBP9099AA6)
    Keywords covid19
    Language English
    Publishing date 2020-05-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa587
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 480: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?

    Pawlotsky, Jean-Michel

    Journal of hepatology

    2019  Volume 71, Issue 6, Page(s) 1070–1072

    MeSH term(s) Antiviral Agents ; Genotype ; Hepacivirus ; Hepatitis C ; Hepatitis C, Chronic ; Humans
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2019-10-21
    Publishing country Netherlands
    Document type Editorial ; Comment
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2019.09.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2027: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: In Memoriam Peter Jansen.

    Beuers, Ulrich / Pawlotsky, Jean-Michel

    Journal of hepatology

    2021  

    Language English
    Publishing date 2021-12-01
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2021.10.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2027: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.

    Pawlotsky, Jean-Michel

    Seminars in liver disease

    2019  Volume 39, Issue 3, Page(s) 354–368

    Abstract: The treatment of chronic hepatitis C virus (HCV) infection has considerably evolved with the development of safe and well-tolerated combinations of direct-acting antiviral (DAA) drugs yielding high rates of infection cure. However, some patients fail to ... ...

    Abstract The treatment of chronic hepatitis C virus (HCV) infection has considerably evolved with the development of safe and well-tolerated combinations of direct-acting antiviral (DAA) drugs yielding high rates of infection cure. However, some patients fail to achieve a sustained virological response while receiving the most recent DAA combinations. Several waves of treatment failures have occurred concomitantly to the use of different drug combinations. The outcome of their retreatment strongly depends on the DAA(s) received and the retreatment regimen(s) available. This article discusses virological failure rates with the successive waves of HCV combination regimens, the reasons for failure, the role of HCV resistance, and current retreatment options. The triple combination of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks is the first-line retreatment strategy in patients previously exposed to DAAs. Difficult-to-retreat patients may benefit from the combination of sofosbuvir plus glecaprevir/pibrentasvir and/or the addition of ribavirin and/or longer retreatment duration.
    MeSH term(s) Antiviral Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Carbamates/therapeutic use ; Drug Combinations ; Drug Resistance, Viral ; Drug Therapy, Combination ; Hepatitis C, Chronic/drug therapy ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; Macrocyclic Compounds/therapeutic use ; Pyrrolidines/therapeutic use ; Quinoxalines/therapeutic use ; Retreatment ; Ribavirin/therapeutic use ; Sofosbuvir/therapeutic use ; Sulfonamides/therapeutic use ; Sustained Virologic Response ; Treatment Failure
    Chemical Substances Antiviral Agents ; Benzimidazoles ; Carbamates ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings ; Macrocyclic Compounds ; Pyrrolidines ; Quinoxalines ; Sulfonamides ; glecaprevir and pibrentasvir ; sofosbuvir, velpatasvir and voxilaprevir ; Ribavirin (49717AWG6K) ; Sofosbuvir (WJ6CA3ZU8B)
    Language English
    Publishing date 2019-04-30
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603177-8
    ISSN 1098-8971 ; 0272-8087
    ISSN (online) 1098-8971
    ISSN 0272-8087
    DOI 10.1055/s-0039-1687823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1752: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top